Açorda

Acorda Therapeutics Announces Nasdaq Delisting Notification

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Pharmaceutical, Health, United States bankruptcy court, Bankruptcy, Merz, Açorda, Therapy, Acorda Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024.
  • The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company.
  • In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York.
  • Once the delisting takes effect, Acorda expects its common stock to begin trading on the Pink Open Market (commonly referred to as the “pink sheets”).

AltPep Appoints Soon Hyouk Lee to Newly Created Position of Chief Business Officer

Retrieved on: 
Wednesday, December 13, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Harvard Business School, Açorda, Therapy, Dartmouth College, Amyloid, Acorda Therapeutics, MBA, Multiple sclerosis, Biology, Pharmaceutical industry

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep.

Key Points: 
  • AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep.
  • In this role, Soon will lead AltPep’s corporate and business development.
  • “We are excited about Soon joining our team,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep.
  • “AltPep is leading critical research in amyloid diseases, adopting a methodical, evidence-based approach that demonstrates a profound understanding of the disease process,” said Soon.

Athersys Director Jane Wasman Appointed Board Chair

Retrieved on: 
Monday, October 2, 2023
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, International, Shareholder, General counsel, Schering-Plough, Stroke, Harvard Law School, Princeton University, Associate, Acorda Therapeutics, Açorda, Regenerative medicine, Organization, SLS, JD, Chairperson, Therapy, Management

Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023.

Key Points: 
  • Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023.
  • Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys’ Audit Committee and previously serving as Chair of its Nominations, Governance & Compliance Committee.
  • “We are delighted that Jane will now be chairing Athersys’ board.
  • “On behalf of the Athersys Board of Directors and the company’s employees, I am honored to assume the responsibilities of Board Chair and to help guide our various initiatives to drive shareholder value,” said Ms. Wasman.

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Pharmaceutical, Health, Neurology, ACOR, Shareholder, SG, Senior, Q&A, Marketing, MIL-PRF-38535, GAAP, Research, 4-Aminopyridine, Patient, Physician, Burns, OPEX, Growth, Acorda Therapeutics, R, Therapy, Cryptocurrency, Video game, Bank, Broadcasting, Finance, Açorda, Webcast

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023.
  • Research and development (R&D) expenses for the quarter ended June 30, 2023 was $1.6 million, compared to $1.5 million for the quarter ended June 30, 2022.
  • Total operating expenses for the quarter ended June 30, 2023 was $33.3 million, compared to $45 million for the same quarter in 2022.
  • The Company will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results today at 4:30 p.m.

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

Retrieved on: 
Wednesday, August 2, 2023
Pharmaceutical, Health, Neurology, COPD, Glaucoma, Mental toughness, Hallucination, Asthma, Psychosis, ACOR, Butyrophenone, Medicine, Education, Wheeze, Friends, Phenothiazine, Somnolence, Fever, Phenelzine, PWP Heavyweight Championship, Dopamine, Açorda, Risperidone, Fighter, Capsule, L-DOPA, Dizziness, Tranylcypromine, Patient, Gambling, Nausea, Confusion, Perspiration, Dyskinesia, Acorda Therapeutics, OFF, Metoclopramide, Upper respiratory tract infection, Therapy, Sleep, Bronchospasm, Family, Saliva, Disease, Pharmaceutical industry, Birth control, Interior design

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.
  • INBRIJA is not to be used by people who have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks.
  • I’m determined to make every day, every moment, count, and to live a full life with my family and friends.
  • The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023

Retrieved on: 
Tuesday, August 1, 2023
Biotechnology, General Health, Neurology, Other Health, Health, Acorda Therapeutics, Therapy, Q&A, Broadcasting, Açorda, Webcast

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m.
  • ET.
  • To access the replay, please dial 1 866 813 9403 (domestic) or +1 929 458 6194 (international); access code 649308.
  • The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com .

ARCH Venture Partners Announces Appointment of Kent Rogers as Venture Partner

Retrieved on: 
Friday, July 14, 2023
Emory University, Schering-Plough, ARCH Venture Partners, Business, MBA, Kent, Acorda Therapeutics, Science, Açorda, ARCH, Business administration, PBM, Health, Therapy, Pharmaceutical industry, Indiana University, UnitedHealth Group, Merck

CHICAGO, July 14, 2023 /PRNewswire/ -- ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Kent Rogers as Venture Partner.

Key Points: 
  • CHICAGO, July 14, 2023 /PRNewswire/ -- ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Kent Rogers as Venture Partner.
  • "Kent brings a long history of creating commercialization strategies to assist ARCH portfolio companies, and we are extremely pleased to have him join the team," said ARCH Managing Director Paul Berns.
  • "ARCH is committed to building innovative companies that impact and improve human health.
  • "I feel privileged to be joining ARCH Venture Partners and look forward to working with proven industry veterans who have successfully driven disruptive innovation through sound investment strategies that back great science and partner with talented leadership to bring cutting-edge discoveries to market," said Rogers.

Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer

Retrieved on: 
Wednesday, May 24, 2023
COPD, Research and development, Doctor of Pharmacy, Diabetes, Internal medicine, Boehringer Ingelheim, NDA, CMO, Acorda Therapeutics, Açorda, EMA, Development, Professional corporation, NTM, MD, Patient, Growth, MAA, FDA, IPF, Therapy, Idiopathic pulmonary fibrosis, MannKind Corporation, Pharmaceutical industry

DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer, effective today.

Key Points: 
  • DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer, effective today.
  • Blank will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company’s executive leadership team.
  • “Burkhard is an accomplished R&D leader and CMO whose experience will be beneficial as we continue to drive our pipeline and future growth,” said Dr. Castagna.
  • Dr. Blank recently served as CMO/Head of R&D at Pharnext SA after serving seven years in the same position at Acorda Therapeutics.

Acorda Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Science, Health, Neurology, Research, ACOR, Shareholder, SG, Senior, Q&A, Internet, Telephone, Biotechnology, Annual Meetings of the International Monetary Fund and the World Bank Group, Ageing, GAAP, Audit committee, Accounting, Burns, Annual general meeting, OPEX, Acorda Therapeutics, R, Therapy, Pharmaceutical industry, Video game, Bank, Finance, Chance, Açorda, Webcast

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2023.
  • For the quarter ended March 31, 2023, the Company reported AMPYRA net revenue of $12.6 million, a 15.4% decrease compared to $14.9 million for the same quarter in 2022.
  • Additionally, for the quarter ended March 31, 2023, the Company reported FAMPYRA royalty revenues of $2.9 million, a 9.3% decrease compared to the same quarter in 2022.
  • Research and development (R&D) expenses for the quarter ended March 31, 2023 were $1.4 million, compared to $1.7 million for the same quarter in 2022.

Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

Retrieved on: 
Monday, May 8, 2023
Seniors, Neurology, Other Health, Biotechnology, Baby Boomers, Pharmaceutical, Consumer, Health, Supply Chain Management, Retail, PD, CMC, Ageing, Acorda Therapeutics, Açorda, Medication, Parkinson's disease, Patient, AIR, M.I.T, OFF, Therapy, Pharmaceutical industry, Chance, Alkermes

Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in China.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in China.
  • By 2030, it is estimated that China will have approximately 5 million people with Parkinson’s diseasedue to its aging population1.
  • “Our agreement with Chance is an important milestone toward providing INBRIJA to the world’s largest population of people with Parkinson’s.
  • “We are excited to be collaborating with Acorda to make INBRIJA available to people suffering from Parkinson’s disease in China.